Background:The COVID-19 novel coronavirus is contagious,and the mortality is higher in the elderly population.Lockdown in different parts of the world has been imposed since January 2020.Chronic subdural haematoma (cS...Background:The COVID-19 novel coronavirus is contagious,and the mortality is higher in the elderly population.Lockdown in different parts of the world has been imposed since January 2020.Chronic subdural haematoma (cSDH) has a unique natural history in which symptoms can be non-specific,and the onset is insidious.This study aims to evaluate the impact of the COVID-19 pandemic on the presentation of cSDH.Methods:Consecutive adult cSDH patients admitted from 1 March 2020 to 30 April 2020 were reviewed.Exclusion criteria including those who had no definite history of head injury or the diagnosis of cSDH were made from a scheduled follow-up scan.Corresponding data during the same period in 2019 were reviewed for comparison.The primary outcome was the interval between the initial head injury and the final radiological diagnosis of cSDH.Secondary outcomes include Markwalder chronic subdural haematoma grade upon admission,length of stay in the acute hospital,and the modified Rankin scale (mRS) upon discharge.Results:For the primary outcome,the average interval between head injury and the diagnosis of cSDH was significantly longer at 56.6 days (49 to 74 days,SD 9.83 days) during the period from March to April 2020,versus 29.4 days (17 to 42 days,SD 8.59 days) in 2019 for the corresponding period (p = 0.00703).There was no significant difference in the functional outcome upon discharge.Conclusions:cSDH patients can present late during the COVID-19 lockdown period.The functional outcome was comparable when operations for drainage were timely performed.展开更多
目的探讨阿托伐他汀辅助钻孔引流术治疗慢性硬膜下血肿（chronic subdural haematoma,CSDH）临床疗效及对患者血清神经元特异性烯醇化酶（neuron specific enolase,NSE）水平的影响。方法选取2014年1月~2016年4月于首都医科大学附属北...目的探讨阿托伐他汀辅助钻孔引流术治疗慢性硬膜下血肿（chronic subdural haematoma,CSDH）临床疗效及对患者血清神经元特异性烯醇化酶（neuron specific enolase,NSE）水平的影响。方法选取2014年1月~2016年4月于首都医科大学附属北京朝阳医院神经外科接受治疗的98例CSDH患者作为研究对象,通过随机数字表法分为对照组46例和观察组52例。对照组患者行钻孔引流术治疗,观察组在对照组基础上给予阿托伐他汀辅助治疗。2个月后,评价比较患者的临床疗效,以及治疗前后中国卒中量表（China stroke scale,CSS）评分和日常生活能力（ability of daily life,ADL）评分,并比较治疗前及治疗后7 d 2组患者的血清NSE水平。结果 CSDH疗效评价显示,观察组治疗总有效率高于对照组（88.5%vs 71.7%,P〈0.05）。2个月后,观察组患者CSS评分低于对照组[（15.89±3.24）分vs.（19.21±4.17）分],ADL评分高于对照组[（95.24±11.36）分vs.（89.05±10.12）分],组间比较差异均有统计学意义（P〈0.05）。治疗后7d,观察组患者血清NSE水平明显低于对照组[（10.38±2.35）U/m L vs.（14.06±2.68）U/m L,P〈0.05）]。结论阿托伐他汀辅助钻孔引流术治疗CSDH能够显著提高临床疗效,改善神经功能及日常生活能力,并降低血清NSE水平。展开更多
文摘Background:The COVID-19 novel coronavirus is contagious,and the mortality is higher in the elderly population.Lockdown in different parts of the world has been imposed since January 2020.Chronic subdural haematoma (cSDH) has a unique natural history in which symptoms can be non-specific,and the onset is insidious.This study aims to evaluate the impact of the COVID-19 pandemic on the presentation of cSDH.Methods:Consecutive adult cSDH patients admitted from 1 March 2020 to 30 April 2020 were reviewed.Exclusion criteria including those who had no definite history of head injury or the diagnosis of cSDH were made from a scheduled follow-up scan.Corresponding data during the same period in 2019 were reviewed for comparison.The primary outcome was the interval between the initial head injury and the final radiological diagnosis of cSDH.Secondary outcomes include Markwalder chronic subdural haematoma grade upon admission,length of stay in the acute hospital,and the modified Rankin scale (mRS) upon discharge.Results:For the primary outcome,the average interval between head injury and the diagnosis of cSDH was significantly longer at 56.6 days (49 to 74 days,SD 9.83 days) during the period from March to April 2020,versus 29.4 days (17 to 42 days,SD 8.59 days) in 2019 for the corresponding period (p = 0.00703).There was no significant difference in the functional outcome upon discharge.Conclusions:cSDH patients can present late during the COVID-19 lockdown period.The functional outcome was comparable when operations for drainage were timely performed.
文摘目的探讨阿托伐他汀辅助钻孔引流术治疗慢性硬膜下血肿（chronic subdural haematoma,CSDH）临床疗效及对患者血清神经元特异性烯醇化酶（neuron specific enolase,NSE）水平的影响。方法选取2014年1月~2016年4月于首都医科大学附属北京朝阳医院神经外科接受治疗的98例CSDH患者作为研究对象,通过随机数字表法分为对照组46例和观察组52例。对照组患者行钻孔引流术治疗,观察组在对照组基础上给予阿托伐他汀辅助治疗。2个月后,评价比较患者的临床疗效,以及治疗前后中国卒中量表（China stroke scale,CSS）评分和日常生活能力（ability of daily life,ADL）评分,并比较治疗前及治疗后7 d 2组患者的血清NSE水平。结果 CSDH疗效评价显示,观察组治疗总有效率高于对照组（88.5%vs 71.7%,P〈0.05）。2个月后,观察组患者CSS评分低于对照组[（15.89±3.24）分vs.（19.21±4.17）分],ADL评分高于对照组[（95.24±11.36）分vs.（89.05±10.12）分],组间比较差异均有统计学意义（P〈0.05）。治疗后7d,观察组患者血清NSE水平明显低于对照组[（10.38±2.35）U/m L vs.（14.06±2.68）U/m L,P〈0.05）]。结论阿托伐他汀辅助钻孔引流术治疗CSDH能够显著提高临床疗效,改善神经功能及日常生活能力,并降低血清NSE水平。
